Achieving Process Understanding and Control in Film Coating - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Process Understanding and Control in Film Coating
The authors describe a QbD study that was performed to optimize a coating system.


Pharmaceutical Technology
Volume 36, Issue 9, pp. s18-s21

Coating tablets involves selecting a specific color and gloss that are used to distinguish a drug product and build brand identity for that product. In addition to the issue of color and gloss, the coating must have appropriate surface-slip properties and adequately adhere to the tablet. The coating process and the materials used in the coating system can be optimized using a quality-by-design (QbD) approach to meet these requirements. The authors describe a QbD study that was performed to optimize a coating system.

Critical quality attributes (CQAs) for a tablet coating are color, slip, gloss, and adhesion. A quality-by-design (QbD) study that uses a statistical design and data analysis can identify the critical process parameters (CPPs) needed to obtain the desired CQAs.


Table I: Quality function deployment for effects of material on coating properties (Spectrablend II Pink, Sensient Pharmaceutical Coating Systems). (ALL TABLES ARE COURTESY OF THE AUTHORS)
CPPs include both the material composition (i.e., formula) and parameters in the coating process. In this study, quality function deployment (QFD) was used to identify the expected effects of material composition on the CQAs. QFD can be used to minimize the number of experiments, which limits experimental error. Based on the QFD shown in Table I, the amount of titanium dioxide (TiO2) and a red dye were identified as the CQAs for color, and it was determined that a mixture design was not necessary to test the effect of material composition on color. Instead, a three-factor full factorial with a center point for color effect was chosen as a practical design of experiment (DOE).


Table II: Experimental coating conditions.
The coating system compositions were studied. The level of red dye (Red 40 Lakes, 12–14% concentrate) and the level of TiO2were varied to set the design space for the color effect. Medium-chain triglyceride (MCT) levels were adjusted to maintain the mass balance. Table II lists the temperature and spray-rate process variables used to test each of the nine coating-system compositions.

A 1200-g batch of placebo tablets was coated with each of the nine coating systems. After spray coating, 3 and 5% weight-gain samples were collected and rolled in the coating pan for additional 5 min. The percentage of weight gain was based on theoretical coating solution consumption and did not account for coating efficiency. A total of 45 coating experiments were conducted, and 90 samples were collected. Samples were tested, with five replicates, for color, gloss, slip, and adhesion.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here